Intratumoral nanoplexed poly I:C BO-112 in combination with systemic anti–PD-1 for patients with anti–PD-1–refractory tumors

Iván Márquez‐Rodas, Federico Longo, María E. Rodríguez-Ruiz, +24

Science Translational Medicine

Neoadjuvant chemo/immunotherapy for the treatment of stages IIIA resectable non-small cell lung cancer (NSCLC): A phase II multicenter exploratory study—NADIM study-SLCG.

Mariano Provencio-Pulla, Ernest Nadal-Alforja, Manuel Cobo, +17

Journal of Clinical Oncology

Surgical OncologyMedicineHigh Response RateNeoadjuvant TreatmentAdjuvant Treatment +10

Initial results from a dose finding study of TNO155, a SHP2 inhibitor, in adults with advanced solid tumors.

Irene Braña, Geoffrey I. Shapiro, Melissa L. Johnson, +12

Journal of Clinical Oncology

Tumor BiologyMolecular PharmacologyDose Finding StudyOncologyReceptor Tyrosine +12

Neoadjuvant chemo-immunotherapy for the treatment of stage IIIA resectable non-small-cell lung cancer (NSCLC): A phase II multicenter exploratory study—Final data of patients who underwent surgical assessment.

Mariano Provencio, Ernest Nadal, Amelia Insa, +16

Journal of Clinical Oncology

Surgical OncologyConventional ChemotherapyPhase IiMedicineCancer Management +12

High Prevalence of Somatic Oncogenic Driver Alterations in Patients With NSCLC and Li-Fraumeni Syndrome

Laura Mezquita, Maria Jové, Ernest Nadal, +28

Journal of Thoracic Oncology

Li-fraumeni SyndromeHigh PrevalencePathologyDermatologyMedicine

Genome-wide profiling of non-smoking-related lung cancer cells reveals common RB1 rearrangements associated with histopathologic transformation in EGFR-mutant tumors

Eva Pros, Maria Saigí, Daniel Alameda, +22

Annals of Oncology

Radiation OncologyMedicineCancer GenomicsEgfr-mutant TumorsBronchial Neoplasm +9

“New” metastases are associated with a poorer prognosis than growth of pre-existing metastases in patients with metastatic breast cancer treated with chemotherapy

Christopher Twelves, Javier Cortés, Peter A. Kaufman, +8

Breast Cancer Research

Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours

Johann S. de Bono, Chia‐Chi Lin, Li‐Tzong Chen, +20

British Journal of Cancer

OA13.05 NADIM Study: Updated Clinical Research and Outcomes

Mariano Provencio, Ernest Nadal, Amelia Insa, +18

Journal of Thoracic Oncology

Clinical EffectivenessClinical EvidenceClinical TrialsClinical ReviewOa13.05 Nadim Study +2

RESILIENT Part 2: A Randomized, Open-Label Phase III Study of Liposomal Irinotecan Versus Topotecan in Adults With Relapsed Small Cell Lung Cancer

David R. Spigel, Afshin Dowlati, Yuanbin Chen, +14

Journal of Clinical Oncology